GlassScriptPhysician profile
Ling Yi Obrand
NPI 1295225399
$262.98
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.67 · 2020: $12.54 · 2021: $16.35 · 2022: $211.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $65.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.41 | 2022 | |
| Alkermes, INC. | $28.89 | 2020-2021 | |
| Pfizer INC. | $18.42 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.06 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.77 | 2019 | |
| Astellas Pharma US INC | $10.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Yi Obrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.